α-bromobenzyl trifluoromethyl ketone | 395-15-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: α-bromobenzyl trifluoromethyl ketone
• 英文别名: 3-Bromo-1,1,1-trifluoro-3-phenylpropan-2-one
• CAS: 395-15-3
• 化学式: C₉H₆BrF₃O
• 分子量: 267.045
• InChiKey: XWQPKCABAXIHPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  α-bromobenzyl trifluoromethyl ketone 在 sodium methylate 作用下， 反应 2.17h， 生成 1,1,1-trifluoro-3-methoxy-3-phenyl-2-propanone
  参考文献：
  名称：

  Karavan, V. S.; Tribulovich, V. G.; Nikiforov, V. A., Journal of Organic Chemistry USSR (English Translation), 1992, vol. 28, # 7, p. 1148 - 1151

  摘要：

  DOI：
• 作为产物：
  描述：

  (Z)-4-(3,3,3-trifluoro-1-phenylprop-1-en-2-yl)morpholine 在 盐酸 、 溴 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 0.08h， 生成 α-bromobenzyl trifluoromethyl ketone
  参考文献：
  名称：

  Halogenation of 1-trifluoromethyl enamines: A new and efficient synthesis of α-bromo- and α-iodo-trifluoromethyl ketones

  摘要：

  Treatment of the 1-trifluoromethyl enamines 1a-d with bromine or iodine results in the formation of the corresponding iminium salts. Treatment of any of these salts with methanol results in the formation of the corresponding alpha-halo-trifluoromethyl ketones.

  DOI：

  10.1016/s0022-1139(96)03453-7

文献信息

• Heteroaryl compounds as P2Y1 receptor inhibitors
  申请人：Sutton C. James

  公开号：US20060173002A1

  公开（公告）日：2006-08-03

  The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y 1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y 1 receptor activity.

  本发明提供了新颖的杂环芳基化合物及其类似物，这些化合物是人类P2Y1受体的选择性抑制剂。该发明还提供了相应的各种药物组合物以及调节P2Y1受体活性治疗对其敏感的疾病的方法。
• IMIDAZOPYRIDAZINONE COMPOUNDS AND USES THEREOF
  申请人：Aduro Biotech, Inc.

  公开号：US20200181153A1

  公开（公告）日：2020-06-11

  The present invention relates to imidazopyridazinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

  本发明涉及咪唑吡啉并嗪酮类化合物。本发明还涉及含有这些化合物的药物组合物，以及通过向需要的受试者投药这些化合物和药物组合物来治疗自身免疫、炎症和神经退行性疾病的方法。本发明还涉及将这些化合物用于研究或其他非治疗目的的用途。
• Nouvelle synthese de trifluoromethylcetones et d' /ga-bromo trifluoromethylcetones
  作者：J.P. Begue、D. Mesureur

  DOI：10.1016/s0022-1139(00)82782-7

  日期：1988.5

  We report a new method for the preparation of trifluoromethylketones, as an alternative to the use of organometallics. The condensation of phosphonium ylides with trimethylsilyl trifluoroacetate provides silyloxy enol ethers whose hydrolysis leads to trifluoromethylketones. Bromation of the same silyloxy enol ether is also a convenient preparation of /ga-bromo trifluoromethylketone.

  我们报告了一种制备三氟甲基酮的新方法，作为使用有机金属的替代方法。磷酰基yl与三氟乙酸三甲基甲硅烷基酯的缩合提供甲硅烷氧基烯醇醚，其水解导致形成三氟甲基酮。相同的甲硅烷氧基烯醇醚的溴化也是γ-溴三氟甲基酮的方便制备。
• Substituted azole derivatives as therapeutic agents
  申请人：——

  公开号：US20040192743A1

  公开（公告）日：2004-09-30

  This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds and their use in treating human or animal disorders. The compounds of the invention may be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes, Type II diabetes.

  这项发明提供了一些可能作为蛋白酪氨酸磷酸酶（PTPases）抑制剂有用的唑类化合物。本发明提供了式（I）的化合物，它们的制备方法，包含这些化合物的制药组合物以及它们在治疗人类或动物疾病中的应用。本发明的化合物可能作为蛋白酪氨酸磷酸酶的抑制剂有用，因此可用于管理、治疗、控制和辅助治疗由PTPase活性介导的疾病，如1型糖尿病、2型糖尿病等。
• HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS
  申请人：Sutton James C.

  公开号：US20100093689A1

  公开（公告）日：2010-04-15

  The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y 1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y 1 receptor activity.

  本发明提供了新型杂环芳基化合物及其类似物，它们是选择性抑制人类P2Y1受体的药物。本发明还提供了各种该药物的制剂和调节P2Y1受体活性治疗疾病的方法。